Skip to main content
Equibles

ACADIAN ASSET MANAGEMENT LLC

Position in FATE — Fate Therapeutics Inc

CIK 916542 Boston, MA
Back to FATE Full portfolio

Position in FATE

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$11,748,375
+$6,804,135 QoQ
Shares Held
4,351,250
+5.6% QoQ
Ownership
3.63%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#5
of 156 holders
Holding Since
Jun 2023
13 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in FATE Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ACADIAN ASSET MANAGEMENT LLC holds $732,389,014 across 168 Biotechnology names. FATE ranks #14 (1.6% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INCY
Incyte Corp
 1,664,999 $188,744,286
2 REGN
Regeneron Pharmaceuticals, Inc.
 157,440 $98,170,137
3 IMCR
Immunocore Holdings plc
 1,209,894 $38,414,134
4 RIGL
Rigel Pharmaceuticals Inc
 591,686 $23,146,756
5 EXEL
Exelixis, Inc.
 421,444 $22,930,768
6 VRTX
Vertex Pharmaceuticals Inc / Ma
 42,122 $20,923,261
7 TBPH
Theravance Biopharma, Inc.
 1,174,910 $19,973,470
8 PRTA
Prothena Corp Public Ltd Co
 2,010,645 $19,684,214

All Filings in FATE

Export CSV
13 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $11,748,375 4,351,250
2026-03-31 $4,944,240 4,120,200
2025-12-31 $2,873,255 2,931,893
2025-09-30 $3,414,894 2,710,234
2025-06-30 $2,755,148 2,459,954
2025-03-31 $1,954,116 2,473,565
2024-12-31 $2,431,756 1,473,792
2024-09-30 $5,607,420 1,602,120
2024-06-30 $6,589,067 2,008,862
2024-03-31 $12,581,670 1,714,124
2023-12-31 $8,531,579 2,281,171
2023-09-30 $4,557,145 2,149,597
2023-06-30 $4,345,484 912,917